TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35524068

Group type: EXPERIMENTAL
Intervention: Abaloparatide
Number of subjects: 11616

Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 11616
Study: 35524223

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infected CKD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched control group of patients
Number of subjects: 0
Study: 35524239

Group type: EXPERIMENTAL
Intervention: Alpelisib 350 mg QD combined with Imatinib 400 mg QD
Number of subjects: 56
Study: 35524363

Group type: EXPERIMENTAL
Intervention: Potential Living Donors (PLDs) present
Number of subjects: 847
Study: 35524404

Group type: EXPERIMENTAL
Intervention: Ultra-high-density mapping (UHDM) system with Lumipoint™ map-analysis tool for assessing residual antral potential (RAP) and pulmonary vein gaps (PVG) during AF ablation.
Number of subjects: 58
Study: 35524434

Group type: EXPERIMENTAL
Intervention: Evidence-based educational intervention for Child Health Services nurses
Number of subjects: 30
Study: 35524904

Group type: EXPERIMENTAL
Intervention: Nissen-Sleeve gastrectomy
Number of subjects: 365
Study: 35525422

Group type: EXPERIMENTAL
Intervention: Acute coronary syndrome (ACS) patients
Number of subjects: 293

Group type: COMPARATOR
Intervention: Control group (non-ACS participants)
Number of subjects: 293
Study: 35525826

Group type: EXPERIMENTAL
Intervention: Early mobilization after knee and hip arthroplasty
Number of subjects: 60
Study: 35525960

Group type: EXPERIMENTAL
Intervention: Novel metabolomic biomarkers
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Acylcarnitine ratio C4/C18:2, apolipoprotein (apo) B, history of heart failure (HF), age > 65 years, presence of acute coronary syndrome
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Higher levels of ceramide ratio C24:1/C24:0, acylcarnitine ratio C4/C18:2, age > 65, peripheral artery disease
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Higher levels of apoA1
Number of subjects: 316
Study: 35525964

Group type: EXPERIMENTAL
Intervention: STOP (Self-regulation Therapy for Opioid addiction and Pain)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: STOP
Number of subjects: 14
Study: 35526031

Group type: EXPERIMENTAL
Intervention: Asili social enterprise program services
Number of subjects: 1733
Study: 35526057

Group type: EXPERIMENTAL
Intervention: Carotid artery intima-media thickness (CIMT) measured at baseline and 2.5 years
Number of subjects: 1495

Group type: EXPERIMENTAL
Intervention: CIMT measured at baseline
Number of subjects: 1495

Group type: EXPERIMENTAL
Intervention: CIMT measured at baseline, stratified by age group (<65 and ≥65 years old)
Number of subjects: 1495
Study: 35526065

Group type: EXPERIMENTAL
Intervention: HIIT-SM (High-Intensity Interval Training Shock Microcycle)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: HIIT-SM with additional LIT (Low-Intensity Training)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 36
Study: 35526096

Group type: EXPERIMENTAL
Intervention: ABL501 (LAG-3xPD-L1 bispecific antibody)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of PD-1/PD-L1 blockade with other checkpoint inhibitors
Number of subjects: 0
Study: 35526201

Group type: EXPERIMENTAL
Intervention: Wysa for Chronic Pain (8-week subscription)
Number of subjects: 51
Study: 35526266

Group type: EXPERIMENTAL
Intervention: Anlotinib plus platinum-etoposide
Number of subjects: 35
Study: 35526308

Group type: EXPERIMENTAL
Intervention: Regorafenib 80 mg and Nivolumab 240 mg every 2 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Regorafenib plus Nivolumab
Number of subjects: 52
Study: 35526537

Group type: EXPERIMENTAL
Intervention: Unvaccinated individuals
Number of subjects: 52

Group type: COMPARATOR
Intervention: Vaccinated individuals
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Clinical phenotype during delta wave
Number of subjects: 52
Study: 35526554

Group type: EXPERIMENTAL
Intervention: Acute surgical evacuation (336 patients, 24% of the study population)
Number of subjects: 1407

Group type: COMPARATOR
Intervention: Initial conservative treatment (982 patients)
Number of subjects: 1407
Study: 35526776

Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 0
Study: 35527353

Group type: EXPERIMENTAL
Intervention: Clinical nutritionist assessment
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Dental hygienist assessment
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Continuous xerostomia
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Poor self-reported oral health
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Edentulous status
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Toothache or problems with dentures
Number of subjects: 250
Study: 35527425

Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)
Number of subjects: 86
Study: 35527798

Group type: EXPERIMENTAL
Intervention: Online Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 28
Study: 35528788

Group type: EXPERIMENTAL
Intervention: Proficiency-based mastery learning on a virtual reality simulator
Number of subjects: 31

Group type: COMPARATOR
Intervention: Pre-training TURBT procedures
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Post-training TURBT procedures
Number of subjects: 31
Study: 35528798

Group type: EXPERIMENTAL
Intervention: Acupoint stimulation
Number of subjects: 0
Study: 35528799

Group type: EXPERIMENTAL
Intervention: Pain self-management intervention (six-week intervention consisting of education, skills building, and nurse coaching)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 21
Study: 35528826

Group type: EXPERIMENTAL
Intervention: Setmelanotide
Number of subjects: 17

Group type: COMPARATOR
Intervention: Traditional interventions (diet, surgery, exercise)
Number of subjects: 17
Study: 35529085

Group type: EXPERIMENTAL
Intervention: Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 0
Study: 35529415

Group type: EXPERIMENTAL
Intervention: Thoracic SBRT
Number of subjects: 48
Study: 35529792

Group type: EXPERIMENTAL
Intervention: Radiomics-based prediction model of STAS
Number of subjects: 99
Study: 35530041

Group type: EXPERIMENTAL
Intervention: Home treatment algorithm including non-steroidal anti-inflammatory drugs, corticosteroids, anticoagulants, oxygen therapy, and antibiotics.
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control cohort with other therapeutic schedules.
Number of subjects: 108
Study: 35530320

Group type: EXPERIMENTAL
Intervention: Baseline metabolic tumor volume (MTV) and Peking criteria from serial positron emission tomography (PET) scans
Number of subjects: 300
Study: 35531468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate 5g
Number of subjects: 196
Study: 35532041

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 1165
Study: 35532858

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 4422
Study: 35532984

Group type: EXPERIMENTAL
Intervention: Advanced Meditation and Vegan Diet
Number of subjects: 0
Study: 35532996

Group type: EXPERIMENTAL
Intervention: Multidisciplinary follow-up involving medical, psychological, and social evaluation at ICU discharge and at 3, 6, and 12 months thereafter.
Number of subjects: 546

Group type: COMPARATOR
Intervention: Standard postintensive care unit (ICU) follow-up, with patients seen only at 12 months by the multidisciplinary team.
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Multidisciplinary follow-up
Number of subjects: 546

Group type: COMPARATOR
Intervention: Standard postintensive care unit (ICU) follow-up
Number of subjects: 546
Study: 35533035

Group type: EXPERIMENTAL
Intervention: Glycopyrronium cloth, 2.4% applied for 30 minutes without occlusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glycopyrronium cloth, 2.4% applied for 30 minutes under occlusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glycopyrronium cloth, 2.4% applied for 15 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glycopyrronium cloth, 2.4% applied overnight without occlusion
Number of subjects: 0
Study: 35533094

Group type: EXPERIMENTAL
Intervention: BREAST-Q expectations questionnaire
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 35533265

Group type: EXPERIMENTAL
Intervention: Anaerobic exercise (AEX)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pre-meal and basal insulin omission
Number of subjects: 21
Study: 35533793

Group type: EXPERIMENTAL
Intervention: Amoxicillin (TDM with ≥1 intermediate and ≥1 trough level performed 24 h after therapy initiation)
Number of subjects: 156
Study: 35533995

Group type: EXPERIMENTAL
Intervention: POSE 2.0 procedure
Number of subjects: 44
Study: 35534047

Group type: EXPERIMENTAL
Intervention: CART2 (anti-CD19, anti-CD22, or anti-CD19/22 CART construct)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lymphodepletion (LD) pre-CART
Number of subjects: 0
Study: 35534083

Group type: EXPERIMENTAL
Intervention: Moral Injury (MI)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Daily stress
Number of subjects: 206

Group type: COMPARATOR
Intervention: PTSD prevalence
Number of subjects: 206

Group type: COMPARATOR
Intervention: CPTSD prevalence
Number of subjects: 206
Study: 35534102

Group type: EXPERIMENTAL
Intervention: Night eating
Number of subjects: 85
Study: 35534310

Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine (Rotarix®)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Non-seroconverted children
Number of subjects: 391
Study: 35534447

Group type: EXPERIMENTAL
Intervention: Laparoscopic proximal gastrectomy with double-tract reconstruction (LPG-DTR)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Laparoscopic total gastrectomy (LTG)
Number of subjects: 138
Study: 35534566

Group type: EXPERIMENTAL
Intervention: CT041 (Claudin18.2-targeted CAR T cells)
Number of subjects: 37
Study: 35534690

Group type: EXPERIMENTAL
Intervention: Induction chemo-immunotherapy (ICIT)
Number of subjects: 31
Study: 35534889

Group type: EXPERIMENTAL
Intervention: Referral to cardiology care
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Facilitators in the referral process
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Barriers in the referral process
Number of subjects: 28
Study: 35535423

Group type: EXPERIMENTAL
Intervention: phIL12 gene electrotransfer (GET)
Number of subjects: 0
Study: 35535576

Group type: EXPERIMENTAL
Intervention: Proteomic signature analysis for presence of coronary artery calcium (CAC > 0)
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Proteomic signature analysis for presence of coronary plaque
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Proteins uniquely related to presence of plaque
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Proteins related only to CAC
Number of subjects: 662
Study: 35535581

Group type: EXPERIMENTAL
Intervention: Minnelide™
Number of subjects: 0
Study: 35535593

Group type: EXPERIMENTAL
Intervention: Global Work Index (GWI)
Number of subjects: 1827

Group type: EXPERIMENTAL
Intervention: Global Constructive Work (GCW)
Number of subjects: 1827

Group type: EXPERIMENTAL
Intervention: Global Wasted Work (GWW)
Number of subjects: 1827

Group type: EXPERIMENTAL
Intervention: Global Work Efficiency (GWE)
Number of subjects: 1827

Group type: EXPERIMENTAL
Intervention: Sex differences in myocardial work indices
Number of subjects: 1827

Group type: EXPERIMENTAL
Intervention: Age and sex relation to myocardial work indices
Number of subjects: 1827

Group type: EXPERIMENTAL
Intervention: Abnormal work indices
Number of subjects: 1827
Study: 35535605

Group type: EXPERIMENTAL
Intervention: Coronary Angiographic Features
Number of subjects: 0
Study: 35535839

Group type: EXPERIMENTAL
Intervention: Delayed cerebral ischemia (DCI) group
Number of subjects: 112
Study: 35536001

Group type: EXPERIMENTAL
Intervention: Symptomatic patients infected with ETEC
Number of subjects: 0
Study: 35536006

Group type: EXPERIMENTAL
Intervention: Dietary intervention assessed through food frequency questionnaire (FFQ) and 24-h dietary recalls (ASA24)
Number of subjects: 0
Study: 35536310

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35536314

Group type: EXPERIMENTAL
Intervention: Elexacaftor/Tezacaftor/Ivacaftor Therapy
Number of subjects: 0
Study: 35536383

Group type: EXPERIMENTAL
Intervention: Bilateral vestibulopathy (BV) patients
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study: 35536413

Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept 125 mg once weekly
Number of subjects: 0
Study: 35536617

Group type: EXPERIMENTAL
Intervention: Biological age estimation model using 9 physiological biomarkers
Number of subjects: 100
Study: 35536667

Group type: EXPERIMENTAL
Intervention: eCoin reimplantation
Number of subjects: 23
Study: 35536669

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CSA) at a starting dose of 9 mg/kg/d
Number of subjects: 10
Study: 35536690

Group type: EXPERIMENTAL
Intervention: Physical Activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise Capacity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body Composition
Number of subjects: 0
Study: 35536733

Group type: EXPERIMENTAL
Intervention: Larotrectinib 100 mg BID (150 mg BID for one patient)
Number of subjects: 24
Study: 35537101

Group type: EXPERIMENTAL
Intervention: Obinutuzumab 1000 mg on days 1, 8, and 15 of cycle 1 and on day 1 of cycles 2 to 6, followed by obinutuzumab maintenance every 2 months for 2 years; Venetoclax 800 mg OD continuously for 6 cycles starting on day 2 of cycle 1
Number of subjects: 25
Study: 35537111

Group type: EXPERIMENTAL
Intervention: AKST4290 (400 mg) orally twice daily for 6 weeks
Number of subjects: 30
Study: 35537408

Group type: EXPERIMENTAL
Intervention: Neoantigen-specific T cell receptors (TCRs)
Number of subjects: 0
Study: 35537411

Group type: EXPERIMENTAL
Intervention: Androgen receptor blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 0
Study: 35537412

Group type: EXPERIMENTAL
Intervention: Interleukin-6 blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-cytotoxic T-lymphocyte-associated antigen 4 (anti-CTLA-4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-program death 1 (anti-PD-1)
Number of subjects: 0
Study: 35537782

Group type: EXPERIMENTAL
Intervention: Camrelizumab (200 mg intravenously every 3 weeks) plus famitinib (20 mg orally once daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus famitinib
Number of subjects: 36
Study: 35537922

Group type: EXPERIMENTAL
Intervention: New LBBB after TAVI
Number of subjects: 2370

Group type: EXPERIMENTAL
Intervention: New PPM after TAVI
Number of subjects: 2370

Group type: COMPARATOR
Intervention: No CA after TAVI
Number of subjects: 2370
Study: 35538105

Group type: EXPERIMENTAL
Intervention: De-escalated adjuvant antibody doublet therapy (trastuzumab and pertuzumab) without chemotherapy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP)
Number of subjects: 98
Study: 35538232

Group type: EXPERIMENTAL
Intervention: Non-vitamin K antagonist oral anticoagulants (NOACs) dabigatran
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-vitamin K antagonist oral anticoagulants (NOACs) rivaroxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticoagulation or antiplatelet therapy
Number of subjects: 0
Study: 35538421

Group type: EXPERIMENTAL
Intervention: Propofol total intravenous anaesthesia (TIVA)
Number of subjects: 4202

Group type: COMPARATOR
Intervention: Inhalational anaesthesia (GAS)
Number of subjects: 4202
Study: 35538495

Group type: EXPERIMENTAL
Intervention: Preoperative high-oral protein load
Number of subjects: 323

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 323
Study: 35538502

Group type: EXPERIMENTAL
Intervention: Primary progressive aphasia (PPA)
Number of subjects: 167191

Group type: EXPERIMENTAL
Intervention: Pending diagnosis, delay between first consultation and first diagnosis, number of different diagnoses before the diagnosis of interest
Number of subjects: 167191

Group type: EXPERIMENTAL
Intervention: Pharmacological and non-pharmacological treatments
Number of subjects: 167191

Group type: EXPERIMENTAL
Intervention: Speech and language therapy (SLT)
Number of subjects: 167191

Group type: COMPARATOR
Intervention: Alzheimer's disease (AD)
Number of subjects: 167191
Study: 35538512

Group type: EXPERIMENTAL
Intervention: NI-1701 (CD47xCD19 bispecific antibody)
Number of subjects: 0
Study: 35538516

Group type: EXPERIMENTAL
Intervention: LCA preservation
Number of subjects: 216

Group type: COMPARATOR
Intervention: LCA nonpreservation
Number of subjects: 216
Study: 35538903

Group type: EXPERIMENTAL
Intervention: Higher protein intake during caloric restriction (CR)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Lower protein intake during caloric restriction (CR)
Number of subjects: 207
Study: 35542387

Group type: EXPERIMENTAL
Intervention: Baseline concentrations of sRAGE isoforms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 0
Study: 35543002

Group type: EXPERIMENTAL
Intervention: Cortical amyloid-β SUVR
Number of subjects: 4492
Study: 35543021

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs) at discharge from a heart centre
Number of subjects: 13463

Group type: EXPERIMENTAL
Intervention: Hospitalizations
Number of subjects: 13463

Group type: COMPARATOR
Intervention: Patient-reported outcomes (PROs)
Number of subjects: 13463
Study: 35543164

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 942

Group type: COMPARATOR
Intervention: Placebo/no DEX
Number of subjects: 942
Study: 35543814

Group type: EXPERIMENTAL
Intervention: One-on-one peer support intervention
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Caregiver ambassador preparatory course and network meetings
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: One-on-one peer support
Number of subjects: 26
Study: 35543874

Group type: EXPERIMENTAL
Intervention: EndoMind CADe system
Number of subjects: 41
Study: 35543963

Group type: EXPERIMENTAL
Intervention: Tepotinib
Number of subjects: 0
Study: 35544156

Group type: EXPERIMENTAL
Intervention: Repeat Xpert assay
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Further testing and sequencing
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Initial Xpert testing with very low bacillary load
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Initial Xpert testing
Number of subjects: 175

Group type: COMPARATOR
Intervention: New tuberculosis patients vs patients needing retreatment
Number of subjects: 175
Study: 35544165

Group type: EXPERIMENTAL
Intervention: emm75 S pyogenes (1-3 × 10^5 CFU)
Number of subjects: 25
Study: 35544287

Group type: EXPERIMENTAL
Intervention: White adolescents
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 309
Study: 35544727

Group type: EXPERIMENTAL
Intervention: First- or second-line systemic therapy for advanced/metastatic CCA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35544759

Group type: EXPERIMENTAL
Intervention: 1% chloroprocaine (40 mL)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2% chloroprocaine (40 mL)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3% chloroprocaine (40 mL)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chloroprocaine
Number of subjects: 15
Study: 35545011

Group type: EXPERIMENTAL
Intervention: Anti-S100A8/A9 antibody
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anakinra (IL-1 receptor antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flo1-2a anti-murine anti-IL-1α monoclonal antibody
Number of subjects: 0

Group type: COMPARATOR
Intervention: XB2001 (specific anti-human IL-1α antibody)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 35545392

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) assessment of atrial fibrosis in the left atrium (LA) at baseline
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group without established cardiovascular disease
Number of subjects: 100
Study: 35545433

Group type: EXPERIMENTAL
Intervention: Hybrid Capture 2 High-Risk test (HC2)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: LINEAR ARRAY HPV Genotyping Test (LA)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Both methodologies (HC2 and LA)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Total HPV detection (HC2)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Type-specific HPV16/18 genotyping (LA)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Total HPV detection or type-specific HPV16/18 detection with a threshold ≥ atypical squamous cells of undetermined significance for abnormal cytology
Number of subjects: 274
Study: 35545657

Group type: EXPERIMENTAL
Intervention: Self-managed lifestyle treatment using a digital tool
Number of subjects: 370
Study: 35545778

Group type: EXPERIMENTAL
Intervention: Pevonedistat alone or in combination with azacitidine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pevonedistat plus azacitidine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pevonedistat
Number of subjects: 23
Study: 35545947

Group type: EXPERIMENTAL
Intervention: Novel multianalyte assay
Number of subjects: 1036

Group type: COMPARATOR
Intervention: Negative assay result
Number of subjects: 1036
Study: 35546043

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg) for 8 weeks
Number of subjects: 208
Study: 35546145

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) 200-300mL with a predefined minimum level of antibodies
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP)
Number of subjects: 797

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 797
Study: 35546205

Group type: COMPARATOR
Intervention: Chronic HCV infection in patients with APAP overdose
Number of subjects: 2999

Group type: EXPERIMENTAL
Intervention: Acute hepatitis C infection
Number of subjects: 2999

Group type: EXPERIMENTAL
Intervention: Anti-HCV seroconversion
Number of subjects: 2999

Group type: EXPERIMENTAL
Intervention: Transplantation due to ALF
Number of subjects: 2999
Study: 35546228

Group type: EXPERIMENTAL
Intervention: Dynamic Work intervention
Number of subjects: 18